Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three inhaled agents—desflurane, oxygen, and nitric oxide—used in anesthesia. Desflurane is a volatile halogenated ether anesthetic with rapid onset and offset due to its low blood-gas solubility. It acts primarily as a positive allosteric modulator at the GABA(A) receptor, also agonizing glycine receptors, antagonizing glutamate receptors (notably NMDA), inducing potassium channels, and inhibiting NADH-ubiquinone oxidoreductase chain 1 and calcium transporting ATPases[8]. Oxygen serves as an essential carrier gas for respiration during anesthesia. Nitric oxide (NO), when used in medical settings (distinct from nitrous oxide), acts as a selective pulmonary vasodilator by activating soluble guanylate cyclase in vascular smooth muscle cells, increasing cGMP levels and causing vasodilation; it is primarily used for pulmonary hypertension but may be included in specialized anesthetic regimens. The combination of these agents can provide general anesthesia with hemodynamic stability while allowing titration of oxygenation and pulmonary vascular resistance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on desflurane + oxygen + nitric oxide.